Silexion Therapeutics Corp. (NASDAQ:SLXN) saw its stock surge 400% after unveiling positive preclinical findings for its investigational pancreatic cancer therapy, SIL204. The data showed the drug successfully reached multiple metastatic sites following systemic administration.
The biotechnology company, which is developing RNA interference treatments targeting KRAS-driven cancers, reported that a subcutaneous dose of SIL204 reached all primary sites of pancreatic cancer spread and produced anti-tumor effects in a mouse model. Researchers observed clear reductions in tumor burden across several organs commonly affected by the disease.
According to the study, a single subcutaneous injection at a mid-range human equivalent dose — one that is planned for future clinical trials — distributed SIL204 to every major metastatic location. By day seven, tumor load had decreased across all tested organs, with statistically significant reductions in both the peritoneum and lungs.
Importantly, the liver, the most frequent site of pancreatic cancer metastasis, also showed meaningful tumor shrinkage. This is critical, as metastatic disease accounts for more than 80% of pancreatic cancer-related deaths.
“These findings provide additional validation for a critical component of our dual-route administration strategy – the ability of subcutaneously delivered SIL204 to reach metastatic sites throughout the body,” said Mitchell Shirvan, Chief Scientific Officer of Silexion.
Beyond pancreatic cancer, Silexion is expanding its research to cell culture studies across various tumor types and KRAS mutations, exploring the broader potential of SIL204 as a pan-KRAS therapy.
The company remains on schedule to submit regulatory applications in late 2025 and early 2026, and aims to launch Phase 2/3 trials of its dual-route administration approach in the first half of 2026.
Silexion Therapeutics stock price
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.